TW201142292A - Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples - Google Patents

Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples Download PDF

Info

Publication number
TW201142292A
TW201142292A TW100106286A TW100106286A TW201142292A TW 201142292 A TW201142292 A TW 201142292A TW 100106286 A TW100106286 A TW 100106286A TW 100106286 A TW100106286 A TW 100106286A TW 201142292 A TW201142292 A TW 201142292A
Authority
TW
Taiwan
Prior art keywords
combination
benefit
egfr
therapeutic
cancer
Prior art date
Application number
TW100106286A
Other languages
English (en)
Chinese (zh)
Inventor
Julia Grigorieva
Heinrich Roder
Maxim Tsypin
Original Assignee
Biodesix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesix Inc filed Critical Biodesix Inc
Publication of TW201142292A publication Critical patent/TW201142292A/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/26—Mass spectrometers or separator tubes
    • H01J49/34—Dynamic spectrometers
    • H01J49/40—Time-of-flight spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/20—Identification of molecular entities, parts thereof or of chemical compositions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Databases & Information Systems (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Oncology (AREA)
  • Evolutionary Computation (AREA)
TW100106286A 2010-02-24 2011-02-24 Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples TW201142292A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33893810P 2010-02-24 2010-02-24

Publications (1)

Publication Number Publication Date
TW201142292A true TW201142292A (en) 2011-12-01

Family

ID=44477214

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100106286A TW201142292A (en) 2010-02-24 2011-02-24 Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples

Country Status (9)

Country Link
US (2) US20110208433A1 (cg-RX-API-DMAC7.html)
EP (1) EP2539704A4 (cg-RX-API-DMAC7.html)
JP (2) JP2013520681A (cg-RX-API-DMAC7.html)
KR (1) KR101556726B1 (cg-RX-API-DMAC7.html)
CN (1) CN102770760A (cg-RX-API-DMAC7.html)
AU (2) AU2011219069C1 (cg-RX-API-DMAC7.html)
CA (1) CA2790928A1 (cg-RX-API-DMAC7.html)
TW (1) TW201142292A (cg-RX-API-DMAC7.html)
WO (1) WO2011106084A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI639001B (zh) 2012-06-26 2018-10-21 美商拜歐迪希克斯公司 用於選擇及淘汰癌症病人接受免疫反應產生療法之質譜方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103339509A (zh) * 2011-01-28 2013-10-02 佰欧迪塞克斯公司 针对激素和联合疗法选择转移性乳腺癌病人的预测性测试
WO2012149299A2 (en) * 2011-04-29 2012-11-01 Celgene Corporaiton Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
JP2015518167A (ja) 2012-05-29 2015-06-25 バイオデシックス・インコーポレイテッドＢｉｏｄｅｓｉｘ Ｉｎｃ 複合的生物試料（例えば、血清）のディープ−ｍａｌｄｉｔｏｆ質量分析方法およびその使用
CA2878441A1 (en) 2012-07-05 2014-01-09 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
WO2015178946A1 (en) * 2014-04-04 2015-11-26 Biodesix, Inc. Treatment selection for lung cancer patients using mass spectrum of blood-based sample
WO2015157109A1 (en) * 2014-04-08 2015-10-15 Biodesix, Inc. Egfr and hgf inhibitor therapy for lung cancer
WO2016054031A1 (en) 2014-10-02 2016-04-07 Biodesix, Inc. Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample
TW201621315A (zh) 2014-12-03 2016-06-16 拜歐迪希克斯公司 使用ｍａｌｄｉ－ｔｏｆ質譜分析以早期偵測高風險群中之肝細胞癌
US11594403B1 (en) 2014-12-03 2023-02-28 Biodesix Inc. Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample
US11152197B2 (en) * 2015-06-24 2021-10-19 City University Of Hong Kong Method of determining cell cycle stage distribution of cells
CN108027373B (zh) 2015-07-13 2021-04-09 佰欧迪塞克斯公司 受益于阻断t细胞程序性细胞死亡1(pd-1)检查点蛋白的配体活化的抗体药物的黑素瘤患者的预测性测试和分类器开发方法
US11710539B2 (en) 2016-02-01 2023-07-25 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
CN106596824A (zh) * 2016-12-30 2017-04-26 广州中大南沙科技创新产业园有限公司 一种lc‑ms/ms法检测血浆中沙利度胺的方法
EP3566054A4 (en) 2017-01-05 2020-12-09 Biodesix, Inc. PROCESS FOR IDENTIFYING CANCER PATIENTS LIKELY TO BENEFIT FROM IMMUNOTHERAPY FOR LASTING SUSTAINABLE SUB-GROUPS OF PATIENTS WHO HAVE A BAD PROGNOSIS GENERALLY
CN109212042B (zh) * 2017-06-30 2022-03-04 齐鲁制药有限公司 一种采用液质联用法测定盐酸培唑帕尼基因毒性杂质的分析方法
EP3676393A4 (en) 2017-09-01 2021-10-13 Venn Biosciences Corporation IDENTIFICATION AND USE OF GLYCOPEPTIDES AS BIOMARKERS FOR DIAGNOSIS AND MONITORING OF TREATMENT
JP7565795B2 (ja) 2017-12-15 2024-10-11 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
US12094587B2 (en) * 2018-03-29 2024-09-17 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
WO2020019095A1 (es) * 2018-07-26 2020-01-30 Universidad Católica Del Maule Proteína rage (receptor de productos finales de glicacíon avanzada) como biomarcador de sensibilidad tumoral y evaluacion de terapia radiologica y radiomimética
CN119139478A (zh) * 2024-10-11 2024-12-17 首都医科大学附属北京胸科医院 一种治疗anxa6+egfr突变的肺腺癌的组合物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4802102A (en) * 1987-07-15 1989-01-31 Hewlett-Packard Company Baseline correction for chromatography
US5291426A (en) * 1991-02-27 1994-03-01 The Perkin-Elmer Corporation Method of correcting spectral data for background
ES2070739B1 (es) * 1993-04-30 1997-06-01 Alcatel Standard Electrica Dispositivo de conversion de interfaces.
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6017693A (en) * 1994-03-14 2000-01-25 University Of Washington Identification of nucleotides, amino acids, or carbohydrates by mass spectrometry
US5672869A (en) * 1996-04-03 1997-09-30 Eastman Kodak Company Noise and background reduction method for component detection in chromatography/spectrometry
US6253162B1 (en) * 1999-04-07 2001-06-26 Battelle Memorial Institute Method of identifying features in indexed data
ATE406627T1 (de) * 2000-06-19 2008-09-15 Correlogic Systems Inc Heuristisches klassifikationsverfahren
WO2002005709A2 (en) * 2000-07-13 2002-01-24 Medi-Physics, Inc. Diagnostic procedures using 129xe spectroscopy characteristic chemical shift to detect pathology in vivo
SG144731A1 (en) * 2000-07-18 2008-08-28 Correlogic Systems Inc A process for discriminating between biological states based on hidden patterns from biological data
EP1355727A4 (en) * 2000-11-16 2007-04-11 Ciphergen Biosystems Inc METHOD OF ANALYSIS OF MASS SPECTRUM
US20020115056A1 (en) * 2000-12-26 2002-08-22 Goodlett David R. Rapid and quantitative proteome analysis and related methods
US20020119490A1 (en) * 2000-12-26 2002-08-29 Aebersold Ruedi H. Methods for rapid and quantitative proteome analysis
US6829539B2 (en) * 2001-04-13 2004-12-07 The Institute For Systems Biology Methods for quantification and de novo polypeptide sequencing by mass spectrometry
US6849121B1 (en) * 2001-04-24 2005-02-01 The United States Of America As Represented By The Secretary Of The Air Force Growth of uniform crystals
US7314717B2 (en) * 2001-04-30 2008-01-01 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
US7113896B2 (en) * 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US6675106B1 (en) * 2001-06-01 2004-01-06 Sandia Corporation Method of multivariate spectral analysis
US7112408B2 (en) * 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
CA2453725A1 (en) * 2001-07-13 2003-01-23 Syngenta Participations Ag System and method of determining proteomic differences
US7016884B2 (en) * 2002-06-27 2006-03-21 Microsoft Corporation Probability estimate for K-nearest neighbor
WO2004019003A2 (en) * 2002-08-23 2004-03-04 Efeckta Technologies Corporation Image processing of mass spectrometry data for using at multiple resolutions
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
CA2521034A1 (en) * 2003-04-02 2004-10-21 Merck & Co., Inc. Mass spectrometry data analysis techniques
EP1636380A2 (en) * 2003-05-30 2006-03-22 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US20050267689A1 (en) * 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
US20050048547A1 (en) * 2003-07-17 2005-03-03 Hongyu Zhao Classification of disease states using mass spectrometry data
EP1649281A4 (en) * 2003-08-01 2007-11-07 Correlogic Systems Inc MULTIPLE HIGH RESOLUTION PROTEOMIC SERUM FEATURES FOR IDENTIFYING EGG CANCER
EP1709442A4 (en) * 2003-12-11 2010-01-20 Correlogic Systems Inc METHOD FOR DIAGNOSING BIOLOGICAL CONDITIONS BY USING A CENTRALIZED ADAPTIVE MODEL AND SAMPLE PREPARATION
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
WO2005117916A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
US20060029574A1 (en) * 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
PL1948180T3 (pl) * 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
US7858390B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7858389B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
KR20090086415A (ko) * 2006-10-27 2009-08-12 조지 매이슨 인털렉춸 프로퍼티즈, 인코퍼레이티드 전이성 결장직장 암에 대한 검정
CN101201355A (zh) * 2006-12-15 2008-06-18 许洋 免疫组质谱检测个体化肿瘤生物标志及疗效试剂盒和方法
ATE531725T1 (de) * 2007-02-27 2011-11-15 Nuclea Biomarkers Llc Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen
CN101329346A (zh) * 2007-06-18 2008-12-24 许洋 检测乳腺癌特征蛋白的优化质谱模型及其制备方法和应用
WO2009036123A1 (en) * 2007-09-11 2009-03-19 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
CN101836991B (zh) * 2009-03-19 2013-05-22 鼎泓国际投资（香港）有限公司 含有索拉非尼、cMet抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
CA2878441A1 (en) * 2012-07-05 2014-01-09 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI639001B (zh) 2012-06-26 2018-10-21 美商拜歐迪希克斯公司 用於選擇及淘汰癌症病人接受免疫反應產生療法之質譜方法

Also Published As

Publication number Publication date
AU2011219069B2 (en) 2014-02-20
KR101556726B1 (ko) 2015-10-02
US20110208433A1 (en) 2011-08-25
CA2790928A1 (en) 2011-09-01
AU2014202716B2 (en) 2016-02-25
WO2011106084A1 (en) 2011-09-01
US20140284468A1 (en) 2014-09-25
EP2539704A4 (en) 2015-12-02
AU2011219069A1 (en) 2012-09-13
KR20130004309A (ko) 2013-01-09
JP2015222257A (ja) 2015-12-10
AU2014202716A1 (en) 2014-06-12
CN102770760A (zh) 2012-11-07
JP2013520681A (ja) 2013-06-06
AU2011219069C1 (en) 2014-07-17
EP2539704A1 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
TW201142292A (en) Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples
Solanki et al. Cell type–specific adaptive signaling responses to KRASG12C inhibition
Krishnan et al. Quantitative analysis of the TNF-α-induced phosphoproteome reveals AEG-1/MTDH/LYRIC as an IKKβ substrate
JP4997345B2 (ja) Ｅｇｆｒ経路を標的にする薬物による治療のための結腸直腸癌患者の選択
TW201028688A (en) Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US20120225954A1 (en) Methods and compositions for the classification of non-small cell lung carcinoma
Rodriguez-Vida et al. Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma
TW201237409A (en) Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy
Wang et al. Phosphoproteomics reveals HMGA1, a CK2 substrate, as a drug-resistant target in non-small cell lung cancer
US20150285817A1 (en) Method for treating and identifying lung cancer patients likely to benefit from EGFR inhibitor and a monoclonal antibody HGF inhibitor combination therapy
KR102067327B1 (ko) 최적의 암 치료를 위한 Her2 단백질 정량
Asmussen et al. MEK-dependent negative feedback underlies BCR–ABL-mediated oncogene addiction
Miao et al. Platelet infiltration predicts survival in postsurgical colorectal cancer patients
WO2020046966A1 (en) Treatment of adenocarcinomas with mapk pathway inhibitors
TWI567391B (zh) 辨識早期肺腺癌病患之次群組之生物標記
Li et al. EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features
Dong et al. Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway
Sevrin et al. Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells
El Hassouni et al. Uridine cytidine kinase 2 as a potential biomarker for treatment with RX-3117 in pancreatic cancer
Yu et al. SLC2A1 boosts the resistance of non-small cell lung cancer to taxanes by stimulating the formation of EPCAM+ cancer stem-like cells via glycolysis
Kim et al. Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma
WO2010028313A2 (en) Phosphoprotein analysis of carcinomas for assessment of drug sensitivity
Drummond et al. Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial
Teng et al. Leupaxin: A Prospective Therapeutic Target for Esophageal Squamous Carcinoma Treatment
Xie et al. Construction and Validation of a Prognostic Model for Immune and Metabolism-related Genes in Laryngeal Squamous Cell Carcinoma